HTG

EQS-News: HomeToGo SE: HomeToGo to Announce 2023 Outlook and Full Year 2022 Financial Results on 30 March 2023

Retrieved on: 
木曜日, 3月 16, 2023
CFO, CEST, Q&A, Frankfurt Stock Exchange, HTG, Interest, Cryptocurrency, Broadcasting

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Luxembourg, 14 March 2023 - HomeToGo SE (Frankfurt Stock Exchange: HTG) will publish its outlook for 2023 and financial results for the full year and fourth quarter of 2022 (ending 31 December 2022) at 7:00 am CEST on 30 March 2023.
  • Dr. Patrick Andrae, Co-founder & CEO, and Steffen Schneider, CFO, will present the outlook and full year results in a conference call at 2:00 pm CEST, followed by a Q&A session for research analysts and investors.
  • The presentation will be held via a live audio webcast, and will be in English, hosted at: https://www.webcast-eqs.com/hometogo-fy22-q422
    Interested participants can register in advance for the conference call - with the opportunity to take part in the Q&A session - at the following address: https://services.choruscall.it/DiamondPassRegistration/register?confirma...
    Following the call, a recording of the audio webcast will be made available on HomeToGo's Investor Relations website: ir.hometogo.de .

Arima Genomics Announces Appointments to its Board of Directors

Retrieved on: 
火曜日, 3月 14, 2023
Research, Genetics, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Disease, Johnson & Johnson, Agilent Technologies, GSK, Labcorp, Quest Diagnostics, Doctor of Philosophy, Genomics, Arima, Roche, Patient, HTG, Pathology, Cancer, Management, Medical imaging

In addition to Dr. Palma and Mr. Hardison, the Arima Genomics Board of Directors consists of Elizabeth Brady, Siddarth Selvaraj, and Xin Huang.

Key Points: 
  • In addition to Dr. Palma and Mr. Hardison, the Arima Genomics Board of Directors consists of Elizabeth Brady, Siddarth Selvaraj, and Xin Huang.
  • “3D genomics is proving to be an increasingly important tool for discerning clinically actionable information for improving human health and disease, especially in cancer,” said Siddarth Selvaraj, PhD., Chief Executive Officer at Arima Genomics.
  • In addition to Arima Genomics, he sits on the boards of BioPorto, Cytek Biosciences, HTG Molecular, and MDXHealth.
  • “There remains a tremendous opportunity to leverage Arima Genomics’ 3D genomics-based solutions towards new research, translational, and clinical applications.”

EQS-News: HomeToGo SE: HomeToGo Reports Impressive Finish to 2022 - IFRS Revenues Slightly Surpass Upgraded Full Year Guidance

Retrieved on: 
水曜日, 3月 1, 2023
HTG, Software as a service, Annual report, Frankfurt Stock Exchange, Traction, Yoy, Preview (subscription service), EUR, Adjustment, Lithium, Film industry, Onshore

The Company announced that FY/22 IFRS Revenues grew 54% YoY to EUR 146 million (vs. EUR 95 million in FY/21).

Key Points: 
  • The Company announced that FY/22 IFRS Revenues grew 54% YoY to EUR 146 million (vs. EUR 95 million in FY/21).
  • This slightly surpasses HomeToGo’s upgraded guidance - around the higher end of a range of EUR 141-146 million - and is well ahead of the initial 2022 guidance of EUR 120-125 million.
  • We’re proud to have concluded 2022 with IFRS Revenues and Adjusted EBITDA around the upper end of our upgraded guidance, improving profitability whilst already building momentum for 2023.
  • In 2022, HomeToGo continued to deliver strong business growth across key pillars, which are reflected in its preliminary results.

EQS-News: HomeToGo SE: HomeToGo Begins 2023 with Record Booking Revenues Backlog, Very Confident to Achieve Adjusted EBITDA Break-Even in 2023

Retrieved on: 
木曜日, 2月 2, 2023
HTG, Preview (subscription service), Yoy, Frankfurt Stock Exchange, Bookkeeping, Film, Video game, EUR

HomeToGo SE: HomeToGo Begins 2023 with Record Booking Revenues Backlog, Very Confident to Achieve Adjusted EBITDA Break-Even in 2023

Key Points: 
  • HomeToGo SE: HomeToGo Begins 2023 with Record Booking Revenues Backlog, Very Confident to Achieve Adjusted EBITDA Break-Even in 2023
    The issuer is solely responsible for the content of this announcement.
  • Given the record Booking Revenues Backlog and a strong start into the year, HomeToGo is very confident to achieve Adjusted EBITDA break-even in the current year.
  • HomeToGo confirms its upgraded 2022 guidance, expecting IFRS Revenues to grow by 48-54% to EUR 141-146 million and an Adjusted EBITDA of EUR (20)-(25) million, with an Adjusted EBITDA margin of (14)-(18)%.
  • Given a resilient travel sector, the strong market and its healthy cash position and record Booking Revenues Backlog as well as the strong trading in the first days of the year, HomeToGo is very confident it will achieve Adjusted EBITDA break-even in 2023.

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

Retrieved on: 
火曜日, 1月 10, 2023
MPH, Hypertriglyceridemia, Hypercholesterolemia, NAFLD, Patent, Prediabetes, HTG, Code, Safety, LDL, Patient, Mothers (Tokyo Stock Exchange), Type 2 diabetes, Tokyo Stock Exchange, NASH, T2DM, Pharmaceutical industry, Hyperlipidemia

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034.
  • Ph.D., MPH., Chief Medical Officer, MediciNova, Inc., commented, “We are very pleased to receive notice that this new patent will be granted.
  • As we already have patents covering similar indications in the U.S., Canada, Europe, Japan, China, and Korea, we believe this additional patent in Brazil could increase the potential value of MN-001.
  • A trial to evaluate the efficacy and safety of MN-001 in patients with T2DM, NAFLD, and HTG is currently ongoing.”

HTG Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event

Retrieved on: 
月曜日, 1月 9, 2023
SVP, Cancer, Therapy, HTG, Precision medicine, IBA Lifesciences, Direct Corporate Access, Drug discovery, Patent, Intelligence, HERE, Pharmaceutical industry

HTG Therapeutics, the company’s drug discovery business unit, has been actively using its transcriptome-informed approach to drug discovery to design and further refine small-molecule chemical libraries throughout 2022.

Key Points: 
  • HTG Therapeutics, the company’s drug discovery business unit, has been actively using its transcriptome-informed approach to drug discovery to design and further refine small-molecule chemical libraries throughout 2022.
  • This drug discovery platform is an integrated transcriptomic machine learning chemistry-based drug discovery engine that is expected to help overcome the traditional challenges of selecting and designing drug candidates by rendering a higher potential for success in development.
  • HTG Therapeutics’ initial therapeutic pipeline is focused on oncology and degenerative neuroscience, emphasizing pharmacologic targets with understood roles in the progression of diseases in these areas.
  • The most advanced discovery program in oncology is a small molecule program for treatment of liquid tumors.

HTG Announces Certain Preliminary 2022 Unaudited Financial Results

Retrieved on: 
金曜日, 1月 6, 2023
HTP, Precision medicine, HTG, Therapy, Pharmaceutical industry

TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022.

Key Points: 
  • Cash and cash equivalents of $12.2 million as of December 31, 2022
    TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022.
  • Actual results may differ materially from these preliminary unaudited results as a result of the completion of year-end closing procedures, final adjustments and other developments arising between now and the time that the company’s financial results are finalized, and such changes could be material.
  • In addition, these preliminary unaudited results are not a comprehensive statement of the company’s financial results for the year ended December 31, 2022, should not be viewed as a substitute for full, audited financial statements prepared in accordance with generally accepted accounting principles, and are not necessarily indicative of the company’s results for any future period.
  • The company expects to announce full 2022 financial results in advance of its quarterly conference call in March 2023.

HTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast Series

Retrieved on: 
水曜日, 12月 28, 2022
KOL, Head, Precision medicine, Ferroptosis, Drug discovery, Therapy, Transcriptome, University of California, Irvine School of Physical Sciences, Toxicity, HTG, Data analysis, University, Senior, RNA, Pharmaceutical industry

Dr. Spitale described how RNA, an information-rich molecule, has the potential to provide valuable insights into the effects, mechanisms of action and toxicity concerns of potential drug compounds.

Key Points: 
  • Dr. Spitale described how RNA, an information-rich molecule, has the potential to provide valuable insights into the effects, mechanisms of action and toxicity concerns of potential drug compounds.
  • Scientists have historically seen the difficulty of scaling RNA profiling as the primary barrier to fully utilizing RNA profiling in drug screening.
  • HTG also provided a real-world example of how its team has used RNA profiling to differentiate between several compounds targeting mTOR in development of its transcriptome-informed approach to drug discovery.
  • HTG's Therapeutics unit is actively using its transcriptome-informed approach to drug discovery to design and further refine small-molecule chemical libraries.

HTG Molecular Diagnostics Announces Closing of a $10 Million Public Offering

Retrieved on: 
金曜日, 12月 23, 2022
Clinical trial, Precision medicine, Research, Park Avenue, Public expenditure, Security (finance), Form, Series, Sale, Prospectus, 3rd Floor, SEC filing, HTG

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Key Points: 
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are approximately $10.0 million.
  • The offering was made only by means of a prospectus which forms a part of the effective registration statement.
  • A final prospectus relating to the offering has been filed with the SEC.

HTG Molecular Diagnostics Announces Pricing of a $10 Million Public Offering

Retrieved on: 
水曜日, 12月 21, 2022
Clinical trial, Precision medicine, Research, Park Avenue, Public expenditure, Security (finance), Form, Series, Sale, Prospectus, 3rd Floor, SEC filing, HTG

The closing of the offering is expected to occur on or about December 23, 2022, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about December 23, 2022, subject to the satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $10.0 million.
  • The offering is being made only by means of a prospectus which forms a part of the effective registration statement.